REGULATORY

Chuikyo Ends Debate on FY2016 Reimbursement Policy Reform; Price-Based Penalty for Suspended Firms Not in Recommendation

February 4, 2016

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Central Social Insurance Medical Council (Chuikyo) wrapped up its discussions on February 3 for the FY2016 reimbursement policy reform to be implemented in April, hammering out supplementary opinions to be attached to its recommendation paper. The supplementary opinions did…

To read the full story

FY2016 Drug Pricing Reform
August 18, 2015

REGULATORY

Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
Expert Calls for AMR Ecosystem to Boost Japan Antibiotic Innovation
June 25, 2026
PMDA Eyes AI as Staffing Shortages Affect Orphan Drug Reviews
June 25, 2026
Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry

By Philip Carrigan

Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…